Mortality Risk for Patients with Cytomegalovirus Retinitis and Acquired Immune Deficiency Syndrome

Kempen, John H.; Jabs, Douglas A.; Wilson, Laura A.; Dunn, James P.; West, Sheila K.; Tonascia, James
November 2003
Clinical Infectious Diseases;11/15/2003, Vol. 37 Issue 10, p1365
Academic Journal
We prospectively followed up 589 patients to evaluate the relationship of anti-cytomegalovirus (CMV) treatment and immune reconstitution in response to highly active antiretroviral therapy (HAART) on the mortality risk of patients with CMV retinitis and acquired immune deficiency syndrome. The use of HAART was associated with an 81% lower mortality rate (95% confidence interval [CI], 74%—86%); it was 96% lower (95% CI, 92%—98%) for those who developed immune recovery and 49% lower (95% CI, 30—63%) for those who did not. Using time-updated multivariate analysis, current systemic anti-CMV treatment was independently associated with a 28% lower mortality rate (95% CI, 8%—43%). On the basis of these results, for patients who continue to have profound immunodeficiency despite HAART, the continued use of HAART and systemic anti-CMV therapy is predicted to reduce the risk of mortality by 65%, over and above the benefits of Pneumocystis carinii and Mycobacterium avium prophylaxis.


Related Articles

  • 9-(1,3-dihydroxy-2-propoxymethyl)guanine for Cytomegalovirus Infections in Patients with the Acquired Immunodeficiency Syndrome. Bach, Michael C.; Bagwell, Sandra P.; Knapp, Nancy P.; Davis, Kent M.; Hedstrom, Peter S. // Annals of Internal Medicine;Sep85, Vol. 103 Issue 3, p381 

    Describes the use of 9-(1,3-dihydroxy-2-propoxymethyl) guanine, a nucleoside antiviral agent for cytomegalovirus infections in AIDS patients. Case reports on the patients; Efficacy of the agent against cytomegalovirus.

  • Reduced Mortality of Cytomegalovirus Pneumonia After Hematopoietic Cell Transplantation Due to Antiviral Therapy and Changes in Transplantation Practices. Erard, Veronique; Guthrie, Katherine A.; Sachiko Seo; Smith, Jeremy; MeeiLi Huang; Jason Chien; Flowers, Mary E. D.; Corey, Lawrence; Boeckh, Michael // Clinical Infectious Diseases;7/1/2015, Vol. 61 Issue 1, p31 

    Background. Despite major advances in the prevention of cytomegalovirus (CMV) disease, the treatment of CMV pneumonia in recipients of hematopoietic cell transplant remains a significant challenge. Methods. We examined recipient, donor, transplant, viral, and treatment factors associated with...

  • Community-Based Interventions for Marginalized Populations. Mitty, Jennifer Adelson; Flanigan, Timothy P. // Clinical Infectious Diseases;6/1/2004 Supplement, Vol. 38, pS373 

    This article presents information on the community based interventions for AIDS patient's care. Combination antiretroviral therapy has led to dramatic reductions in morbidity and mortality among patients with HIV/AIDS, including those who present with advanced AIDS and very low CD4+ cell counts....

  • Clinical Progression Rates by CD4 Cell Category Before and After the Initiation of Combination Antiretroviral Therapy (cART). Guiguet, Marguerite; Porter, Kholoud; Phillips, Andrew; Costagliola, Dominique; Babiker, Abdel // Open AIDS Journal;2008, Vol. 2, p3 

    Objective: Rates of AIDS defining event (ADE), serious ADE and death by CD4 and HIV RNA categories before and after combination antiretroviral therapy (cART) initiation are lacking for high CD4 counts. Methods: Event rates were estimated within CD4 cell strata using a Poisson regression model...

  • WHO pledges massive effort to increase ARV treatment.  // Essential Drugs Monitor;2003, Issue 33, p7 

    Reports on the plan of the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS to provide antiretroviral treatment to AIDS patients by the end of 2005. Views of WHO director-general Lee Jong-wook, on the plan; Number of HIV-infected persons in 2003; Simplification...

  • Patient factors impacting antiretroviral drug adherence in a Nigerian tertiary hospital. Falang, Kakjing D.; Akubaka, P.; Jimam, N. S. // Journal of Pharmacology & Pharmacotherapeutics;Apr2012, Vol. 3 Issue 2, p138 

    Objective: To study the adherence levels and explore factors impacting them in out-patients on antiretroviral therapy (ART) at the AIDS Prevention Initiative in Nigeria antiretroviral clinic of the Jos University Teaching Hospital. Materials and Methods: We administered a structured...

  • HIV and Hyperlipidemia: Current Recommendations And Treatment. Capili, Bernadette; Anastasi, Joyce K. // MEDSURG Nursing;Feb2006, Vol. 15 Issue 1, p14 

    The article discusses the Highly Active Antiretroviral Therapies (HAART) as a big factor in fighting HIV and AIDS. Cardiovascular disease is also recognized as one of the subsequent diseases which is a result from AIDS virus. It was found out that this life threatening condition has now become...

  • Highly active antiretroviral therapy in Brazil: the challenge of universal access in a context of social inequality. Hacker, Mariana A.; Petersen, Maya L.; Enriquez, Melissa; Bastos, Francisco I. // Revista Panamericana de Salud Publica;Aug2004, Vol. 16 Issue 2, p78 

    Objective. To investigate trends in AIDS mortality and incidence in Brazil over the period of 1984 to 2000 and to assess the impact of the introduction of universal access to highly active antiretroviral therapy (HAART) in the country in 1996. Methods. Data from the Brazilian disease...

  • Tenofovir and Nephrotoxicity. Joshi, Amit; Kraus, Mark // Kidney;Nov/Dec2005, Vol. 14 Issue 6, p255 

    The article provides information on the development of antiretroviral drug tenofovir for the treatment of HIV/AIDS. Tenofovir is an acyclic nucleoside phosphonate in the class of nucleotide reverse transcriptase inhibitors. The drug interrupts DNA synthesis by terminating the elongation of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics